2072-2073 / 2351
Patients at Risk
Survival Time [Months]
CTX only
CET + CTX
220
173
127
83
65
47
19
8
1
222
184
153
118
82
57
30
15
3
HR (95%CI): 0.797 (0.644, 0.986)
Strat. log-rank test: 0.0362
CTX only
Cetuximab + CTX
Survival Probability
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
3
6
9
12
15
18
21
24
|
| |
|
|
| |
| || ||| | || | |
| | | || | | | | ||
| |
| | || ||
| |
| |
|
|
|
|
|
| | |||| || | | | | || || | | | || | | |
|| | | |
| | |
10.1
mo
7.4
mo
Vermorken et al, NEJM 2008
Extreme trial